We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Robot Screening System Streamlines Discovery of New Drug Compounds

By LabMedica International staff writers
Posted on 23 Feb 2015
Print article
Image: Eve, the robot scientist (Photo courtesy of the University of Manchester.
Image: Eve, the robot scientist (Photo courtesy of the University of Manchester.
British drug developers have automated the drug discovery process by using a "robot scientist" to screen thousands of potential candidate compounds.

Investigators at the University of Cambridge (United Kingdom) and the University of Manchester (United Kingdom) described the development of the robot scientist "Eve" in the February 4, 2015, online edition of the journal Interface. Eve is a laboratory automation system that uses artificial intelligence (AI) techniques to discover scientific knowledge through cycles of experimentation. The system integrates and automates library-screening, hit-confirmation, and lead generation through cycles of quantitative structure activity relationship learning and testing.

In practice, Eve systematically tested up to 10,000 compounds per day in the standard brute-force way of conventional mass screening. In addition, Eve selected at random a subset of the library to identify compounds that passed the first screening analysis. Any "hits" were re-tested multiple times to reduce the probability of false positives. Taking this set of confirmed hits, Eve used statistics and machine learning to predict new structures that might score better against the assays. In this fashion, Eve repositioned several drugs against specific targets in parasites that cause tropical diseases. One important validated discovery was that the anti-cancer compound TNP-470 was a potent inhibitor of dihydrofolate reductase from the malaria-causing parasite Plasmodium vivax.

“Eve exploits its artificial intelligence to learn from early successes in her screens and select compounds that have a high probability of being active against the chosen drug target. A smart screening system, based on genetically engineered yeast, is used. This allows Eve to exclude compounds that are toxic to cells and select those that block the action of the parasite protein while leaving any equivalent human protein unscathed. This reduces the costs, uncertainty, and time involved in drug screening, and has the potential to improve the lives of millions of people worldwide,” said contributing author Dr. Stephen G. Oliver, professor of biochemistry at the University of Cambridge.

Senior author Dr. Ross King, professor of biotechnology at the University of Manchester, said, “Every industry now benefits from automation and science is no exception. Bringing in machine learning to make this process intelligent—rather than just a "brute force" approach—could greatly speed up scientific progress and potentially reap huge rewards.”

Related Links:

University of Cambridge
University of Manchester


Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Urine Drug Test
Instant-view Methadone Urine Drug Test
New
Urine Collection Container
Urine Monovette

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The bowel cancer breakthrough could result in better treatment outcomes (Photo courtesy of 123RF)

New RNA Molecules Can Help Predict Bowel Cancer Return Recurrence

Colorectal cancer accounts for 10% of all cancer-related deaths worldwide and was ranked as the second most common cause of cancer death in the United States in 2022. Currently, clinicians face diagnostic... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.